pemigatinib 13.5 MG Oral Tablet [Pemazyre]

RxCUI: 2359340
RxNorm name: pemigatinib 13.5 MG Oral Tablet [Pemazyre]
Display name: pemigatinib 13.5 MG Oral Tablet [Pemazyre]
Full name: pemigatinib 13.5 MG Oral Tablet [Pemazyre]
Term type: SBD
Status: DailyMed mapping
Updated: 2026-06-04 23:39:10

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
PEMAZYRE	PEMIGATINIB	Incyte Corporation	9e1f2222-1d89-4e63-989c-ccebe2ab1eb4	2026-06-09	Warnings, Adverse reactions	Exact identifier rxcui: 2359340

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
9e1f2222-1d89-4e63-989c-ccebe2ab1eb4	Pemazyre 13.5 MG Oral Tablet [PSN] · pemigatinib 13.5 MG Oral Tablet [Pemazyre] [SBD] · Pemazyre 13.5 MG Oral Tablet [SY]	3	15	These highlights do not include all the information needed to use PEMAZYRE safely and effectively. See full prescribing information for PEMAZYRE . PEMAZYRE® (pemigatinib) tablets, for oral use Initial U.S. Approval: 2020	20230614